anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sterile pharmaceutical stable autoclaved clear aqueous compositions of propofol (2,6-Diisopropyl phenol) suitable for parenteral administration are described. The compositions essentially consist of a complex of propofol with 2-hydroxypropyl-beta-cyclodextrin in a weight ratio of 1:30 - 1:60. This complex of propofol with 2-hydroxypropyl-beta-cyclodextrin produces a clear aqueous composition that is stable to autoclaving. The composition is effective as an anaesthetic agent. The process of making these synergistic compositions has been described. 34 claims
PURPOSE:The titled pack, containing a film-forming agent, water, an alcohol and phenol having the color change interval in the alkaline region and a pH indicator  and a pH buffer agent in a specific proportion, adjusted to a specific pH value, and capable of discriminating the peeling time of the formed film by the color change of the indicator. CONSTITUTION:A film type pack, containing 5-30wt% film-forming agent e.g. polyvinyl alcohol, 60-85wt% water, 5-30wt% alcohol and a phenolic pH indicator, e.g. phenol Red, having the color change interval in the alkaline region and a pH buffer agent, and adjusted to a pH 0.2-0.5, preferably 0.3-0.4 higher than the color change point of the pH indicator. The content of the pH buffer agent is preferably 1-5wt%. The peeling time of the formed film can be discriminated by the  color change of the film at a peelable point of 40-50% moisture content.
<P>PROBLEM TO BE SOLVED: To provide a gel-like substance which can be used as a moisturizing agent, is applied on the skin to prevent the dryness of the skin, has good touch, when directly applied on the skin, and smoothens the surface of the skin, when applied on the skin.  <P>SOLUTION: This gel-like substance is characterized by making a moisture-retaining polymer (water-absorbing polymer) powder having a particle diameter of 20 to 50μm to absorb 50 to 200-fold wt. amount of water to form the gel. The method for producing the gel-like substance is characterized by adding water to the powder of a moisture-retaining polymer and simultaneously stirring the mixture at a high rotation rate to make the polymer to absorb 50 to 200-fold wt. amount of the water.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The present disclosure provides binding agents, particularly, antibodies, that comprise variable regions comprising humanized framework regions. Nucleic acids that encode one or both of the variable chains of the binding agents of the present disclosure are also provided, as are cells that include such nucleic acids. Also provided are compositions, including in some instances, pharmaceutical compositions, that include the binding agents disclosed herein. Methods of making and using the binding agents of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having a cell proliferative disorder a therapeutically effective amount of a binding agent disclosed herein, where the binding agent is administered to the individual to enhance an immune response, e.g., a T cell response, to abnormally proliferating cells. The binding agents are also useful in various diagnostic, and monitoring applications, which are also provided.
Patients undergo high-dose radiotherapy of the prostate and seminal vesicles using intensity-modulated radiotherapy (IMRT)\* or 3D-conformal radiation therapy (3D-CRT)\* once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo permanent prostate implant (PPI) brachytherapy or high-dose rate brachytherapy (I 125 or Pd 103 may be used as the radioisotope).
Cadmium (Cd) is a toxic heavy metal that causes nephrosis, including acute kidney injury. To prevent and treat acute kidney injury (AKI) following Cd exposure, a tripeptide, Ser-Arg-Pro (SRP), from Sipunculus nudus L. was employed, and its potential efficacy in AKI was assessed. Oral administration of SRP significantly alleviated Cd-induced kidney damage, leading to improved renal function and the attenuation of structural abnormalities. A network pharmacology analysis revealed the potential of SRP in renal protection by targeting various pathways, including mitogen-activated protein kinase (MAPK) signaling, inflammatory response, and apoptosis pathways. Mechanistic studies indicated that SRP achieves renal protection by inhibiting the activation of MAPK pathways (phosphorylation of p38, p56, ERK, and JNK) in the oxidative stress cascade, suppressing inflammatory responses (iNOS, Arg1, Cox2, TNF-α, IL-1β, and IL-6), and restoring altered apoptosis factors (caspase-9, caspase-3, Bax, and Bcl-2). Hence, SRP has the potential to be used as a therapeutic agent for the treatment of Cd-induced nephrotoxicity.
Compositions and methods for treating or reducing the severity of occurrence of a parasitic worm or helminth infection in a subject are described. The methods include administering to the subject a therapeutically effective amount of a composition comprising isolated native, bioactive nematicidal crystals formed from a single type of nematicidal crystal protein.    The isolated native, bioactive nematicidal crystals are substantially free of any bacterial spores or host bacterial proteins, other than nematicidal crystal protein in the form of a crystal. Methods for making isolated native, bioactive nematicidal crystals are also described. The crystal proteins may be full length, truncated, variant, or sub-variant Cry proteins. Examples of crystal proteins include Cry5B, Cry21, Cry14A, Cry6A, and Cry13A.
The invention relates a novel load method of a camptothecin anti-cancer drug. A segmented copolymer of poly(N-3-aminopropyl methyl acrylamide hydrochloride)-b-poly(N-isopropyl acrylamide) can be synthesized by utilizing a reversible addition-fragmentation chain transferring polymerization method, a camptothecin organic solution is uniformly mixed with the segmented copolymer, a polymer micelle with the camptothecin is synthesized under the stimulation of the temperature, and then the glutaraldehyde or glutaric acid small molecular crosslinking agent is used for conducting the shell crosslinking reaction for the polymer micelle. A camptothecin drug carrier prepared by utilizing the method has excellent drug carrying performance, so that the camptothecin can be rapidly and high efficiently adsorbed under a certain concentration condition, but also the camptothecin can be timely, high efficiently and targetedly released in a specific environment. The method has the advantages of easy operation, high yield, low cost, no environmental pollution, wide application prospect and the like. The prepared camptothecin anticancer drug is a new generation high-performance drug carrier product and also can be used for conveying other anti-cancer drugs which are difficult to dissolve in the human body. The method is particularly applicable to the medical field for researching the tumor cells.
INTRODUCTION: Adult-onset Still's disease is a rare systemic autoinflammatory disease. We present a case of a young man with a constellation of symptoms and myopericarditis as a complication of this disease.
CASE: A 36-year-old Hispanic man with no significant past medical history developed a quotidian fever pattern following an upper respiratory tract infection. He initially presented with chest pain concerning for myocardial infarction and underwent cardiac catheterization, which revealed non-obstructive coronary artery disease. He was found to have myopericarditis, significant neutrophilic leukocytosis, and hyperferritinemia. He improved on high-dose corticosteroids but developed steroid-induced psychosis, and 4 months from symptom onset, he finally received tocilizumab, which eventually induced remission without adverse reactions.
DISCUSSION: Adult-onset Still's disease should be considered in a patient with fevers of undetermined origin. Due to its multisystemic involvement, adult-onset Still's disease is often a diagnosis arrived at after an extensive cardiac, hematologic, malignant, and infectious workup. Imaging, laboratory testing, and bone marrow biopsy were necessary to rule out alternative etiologies of this patient's presentation. Steroids are the mainstay of treatment because they are easily affordable, although the high risk of adverse effects makes them less desirable. Interleukin-1 inhibitors (anakinra or canakinumab) and interleukin-6 inhibitor tocilizumab are the steroid-sparing biologic agents of choice but are cost-prohibitive.
CONCLUSION: Adult-onset Still's disease should be considered in the differential diagnoses of fever of undetermined origin. Early identification and initiation of treatment are critical to faster recovery and prevention of progression to severe complications. Steroids remain the standard first-line therapy and should be followed by disease-modifying steroid sparing drugs. The social determinants of health may preclude their timely initiation and should alert providers of proactive ways to avoid further delays.
Bevacizumab 7.5 mg/kg every 3 weeks will be administered interavenously (IV) to the enrolled patients. Oral capecitabine 1000 mg/m\^2 twice daily for 14 days followed by 7 days off every 21 days. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of patient consent.
The invention relates to biotechnology, immunology and virology. The claimed agent can be used for the prevention of diseases caused by severe acute respiratory syndrome virus SARS-CoV-2. The technical aim of the claimed group of inventions is to create agents containing a single active component and along with this ensuring the effective induction of immune response to the SARS-CoV-2 virus among broad strata of the population.   tris                                 from 0.0180 to 0.0338 sodium chloride                      from 0.1044 to 0.1957 sucrose                              from 5.4688 to 10.2539 magnesium chloride hexahydrate       from 0.0015 to 0.0028 EDTA                                 from 0.0003 to 0.0005 polysorbate-80                       from 0.0037 to 0.0070 water                                the remaining part. The technical result is the creation of an agent which ensures the development of humoral and cell-mediated immune responses to the SARS-Cov-2 virus among broad strata of the population. With that, the agent is intended for intranasal or intramuscular administration. Also, the agent can be administered concomitantly and simultaneously via intranasal and intramuscular routes.   Date Recue/Date Received 2022-04-06
Rapid climate changes, with higher warming rates during winter and spring seasons, dramatically affect the vernalization requirements, one of the most critical processes for the induction of wheat reproductive growth, with severe consequences on flowering time, grain filling, and grain yield. Specifically, the Vrn genes play a major role in the transition from vegetative to reproductive growth in wheat. Recent advances in wheat genomics have significantly improved the understanding of the molecular mechanisms of Vrn genes (Vrn-1, Vrn-2, Vrn-3, and Vrn-4), unveiling a diverse array of natural allelic variations. In this review, we have examined the current knowledge of Vrn genes from a functional and structural point of view, considering the studies conducted on Vrn alleles at different ploidy levels (diploid, tetraploid, and hexaploid). The molecular characterization of Vrn-1 alleles has been a focal point, revealing a diverse array of allelic forms with implications for flowering time. We have highlighted the structural complexity of the different allelic forms and the problems linked to the different nomenclature of some Vrn alleles. Addressing these issues will be crucial for harmonizing research efforts and enhancing our understanding of Vrn gene function and evolution. The increasing availability of genome and transcriptome sequences, along with the improvements in bioinformatics and computational biology, offers a versatile range of possibilities for enriching genomic regions surrounding the target sites of Vrn genes, paving the way for innovative approaches to manipulate flowering time and improve wheat productivity.
Men at least 18 years of age with metastatic prostate cancer may be eligible for this study .Volunteers that meet the eligibility criteria will be considered for study participation regardless of race or ethnic background. Only individuals who can understand and give informed consent will be eligible to participate in this study.
PURPOSE: To obtain a skin care preparation blended with a specified film forming agent and having improved stickiness to the skin. CONSTITUTION: A film forming agent made of aq. latex of crosslinkable polydiorganosiloxane is incorporated into a skin care preparation by 5-20 wt.% to obtain the objective cosmetics used as an anti-suntan agent, cosmetics for eyes, etc. The film forming agent is obtd. as follows; polydiorganosiloxane represented by the formula HO(R2 SiO)x H [R is a methyl, ethyl, propyl, etc., and (x) is 3-100] is mixed with a surface active anionic catalyst and water to prepare an oil-in-water emulsion. This emulsion is additionally mixed with silane represented by the formula R'a Si(OR<3> )4-a [R' is 1-12C hydrocarbon, R<3> is 1-6C alkyl and (a) is 0 or 1], a hydrolyzate of the silane and an alkoxy silicon compd, and is held at 15-30 deg.C for >=5 hr until a crosslinked polymer emulsion is formed. The formed emulsion is mixed with a silica sol or silsesquioxane, if necessary and water is removed.
PURPOSE:To hot-melt and mold granular plastic in a mold by a method wherein an adequate amount of the chemical-containing granular plastic is packed to a mold made of material which is not heated by high frequency electromagnetic field and does not shield electromagnetic field, and after that high frequency electromagnetic field is applied to said mold. CONSTITUTION:First, EVA (ethylene-vinyl acetate copolymer) is used to prepare chemical-containing granular plastic by pregnating plastic material with a suitable chemical. On the other hand, a mold for a desired product is made of a material which is not heated by high frequency electromagnetic field. Secondly, said chemical-containing granular plastic is packed in the mold. Thirdly, the covered mold is placed in a high frequency heater in order to hot-melt only the chemical-containing granular plastic in the mold by applying high frequency electromagnetic field to the mold. Because the chemical-containing granular plastic in the mold is heated from its interior in a short time, the temperature of the product does not go higher than the necessary temperature. Accordingly, the chemical in the plastic scarcely volatilizes and the plastic can be molded without causing a change in property or a deterioration due to heat.
The invention provides a composite emulsion rich in eucommia male flower skin care active ingredient and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine cosmetics. The composite emulsion is prepared from eucommia male flower extract, an emulgator, a lipid material, a thickening agent, essence and deionized water. The method comprises the following steps of 1 a preparation method of the eucommia male flower extract and 2 preparation of the composite emulsion containing the eucommia male flower extract. The composite emulsion and the preparation method thereof have the advantages that a subsection extraction and ceramic micro-membrane separation and concentration process is adopted in preparation of the eucommia male flower extract, and the extract is rich in eucommia male flower flavone, phenols, ursolic acid and other natural antioxidant and bactericidal active ingredients. The modern composite emulsification technology is adopted, the prepared eucommia male flower skin care composite emulsion beatifying cosmetics are high in functional ingredient content and light in color, and have the functions of fast removing skin impurities and free radicals, collagen elastic fibers in epidermis are made to be tough, and expansibility is enhanced. Hair follicles and the deep skin layer can also be cleaned, pores are thinner and smaller, and therefore the skin looks finer, smoother and more lubricative, and the good effect of improving and protecting the skin is achieved.
Bexarotene gel, 1% may cause fetal harm when administered to a pregnant woman.

Bexarotene gel must not be given to a pregnant woman or a woman who intends to become pregnant. If a woman becomes pregnant while taking bexarotene gel, bexarotene gel must be stopped immediately and the woman given appropriate counseling.

Bexarotene caused malformations when administered orally to pregnant rats during days 7 to 17 of gestation. Developmental abnormalities included incomplete ossification at 4 mg/kg/day and cleft palate, depressed eye bulge/microphthalmia, and small ears at 16 mg/kg/day. At doses greater than 10 mg/kg/day, bexarotene caused developmental mortality. The no-effect oral dose in rats was 1 mg/kg/day. Plasma bexarotene concentrations in patients with CTCL applying bexarotene gel, 1% were generally less than one hundredth the Cmax associated with dysmorphogenesis in rats, although some patients had Cmax levels that were approximately one eighth the concentration associated with dysmorphogenesis in rats.

Women of child-bearing potential should be advised to avoid becoming pregnant when bexarotene gel is used. The possibility that a woman of child-bearing potential is pregnant at the time therapy is instituted should be considered. A negative pregnancy test (e.g., serum beta-human chorionic gonadotropin, beta-HCG) with a sensitivity of at least 50 mIU/L should be obtained within one week prior to bexarotene gel therapy, and the pregnancy test must be repeated at monthly intervals while the patient remains on bexarotene gel. Effective contraception must be used for one month prior to the initiation of therapy, during therapy and for at least one month following discontinuation of therapy; it is recommended that two reliable forms of contraception be used simultaneously unless abstinence is the chosen method. Male patients with sexual partners who are pregnant, possibly pregnant, or who could become pregnant must use condoms during sexual intercourse while applying bexarotene gel and for at least one month after the last dose of drug. Bexarotene gel therapy should be initiated on the second or third day of a normal menstrual period. No more than a one month supply of bexarotene gel should be given to the patient so that the results of pregnancy testing can be assessed and counseling regarding avoidance of pregnancy and birth defects can be reinforced.
Central retinal vein occlusion (CRVO) is a common retinal vascular disorder with potentially complications like reduced vision resulting from extensive intraretinal hemorrhage, retinal ischemia and persistent macular edema and neovascular glaucoma secondary to iris neovascularization. Macular edema is a common cause of severe visual loss in both branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Natural history data indicate that CRVO patients presenting with poor visual acuity (_20/200) have an 80% chance of being left with visual acuity less than 20/200 at final visit, whether the CRVO is ischemic or nonischemic at presentation. Treatments that target the secondary effects of venous occlusion, such as grid laser photocoagulation for macular edema and prophylactic panretinal laser photocoagulation for nonperfused CRVO, were shown to be ineffective in improving visual acuity in the Central Vein Occlusion Study (CVOS). Although panretinal photocoagulation is advocated for reducing the risk of neovascular glaucoma in patients with ischemic CRVO, recent clinical trials have failed to demonstrate any significant benefit with laser photocoagulation in the treatment of macular edema due to CRVO. A number of other treatment options are sometimes used in cases of CRVO, such as oral corticosteroids, intravitreal steroids, vitrectomy, hemodilution, intravitreal tissue plasminogen activator, hyperbaric oxygen, and laser or surgical chorioretinal anastomosis. Studies demonstrating the effectiveness of these treatments are inconclusive, although some benefits have been suggested in recent reports. In recent studies the benefit of antiVEGF agents in improving the macular edema due to CRVO have been shown. In this study we are going to compare the effect of intravitreal antiVEGF (Avastin) with combination of Avastin and Triamcinolon in improving the visual acuity and macular thickness in patients with recent (Less than 6 months) CRVO.
Castration-resistant prostate cancer patients eligible for 2nd line hormonal treatment will undergo treatment with Enzalutamide (XTANDI). Subjects will receive 1dd 160 mg Enzalutamide orally continuously until progressive disease occurs.

All subjects will undergo 18F-FDG PET/CT scans at baseline, 2 weeks, 2 and 6, 9 and 12 months after starting androgen receptor-directed treatment. All subjects will undergo Whole Body MRI at baseline, 6, 9 and 12 months. Bone scans will be performed at baseline, 3 months, 6 and 12 months. PSA will be measured at baseline and every 4 weeks thereafter until at 12 months. CTC counts and characteristics will be measured at baseline and during Enzalutamide treatment.
Subjects will receive at time 0 the educational tools (pamphlet-including a graphic-based summary, a magnet and a 12 minutes video). They will then have to answer a questionnaire 1 month later about knowledge, anxiety and satisfaction.
546,589. Medicines. HOPKINS, L. Jan. 9, 1941, No. 319. [Class 81 (i)] A medicinal preparation is made by treating a mixture of zinc, tannic acid, rhatany and alum with hydrochloric acid, allowing the mixture to stand, adding arnica and poppy flowers, allowing to stand for a further period and adding marshmallows and linseed seed and filtering after a further period. Proportions are stated in the Specification. Ether may be added.
The invention relates to a preparation for shortening the course of acute exacerbation of chronic obstructive pulmonary disease, which comprises the following raw materials of 10-20 parts of astragalus particles, 7-17 parts of codonopsis pilosula particles, 4-13 parts of fried perilla seed particles, 4-13 parts of lepidium seed particles, 7-17 parts of angelica particles, 10-20 parts of rhodiola rosea particles, 1-11 parts of schisandra particles, 4-13 parts of dried orange peel particles, 1-11 parts of polygala tenuifolia particles, 4-13 parts of ginger magnolia bark particles, 4-13 parts of rhizoma pinelliae preparata particles, 4-13 parts of radix curcumae particles, 4-13 parts of thunberg fritillary bulb particles and 1-11 parts of epimedium particles. The invention also discloses a preparation method of the preparation. The medicine principle of the preparation is based on phlegm and blood stasis removal and qi and yin benefiting, and the rhodiola rosea has the effects of tonifying qi and activating blood, and dredging collaterals and relieving asthma and can effectively remove phlegm and blood stasis by matching with the astragalus as a monarch drug. The codonopsis pilosula and the angelica are monarch drugs and have the effects of tonifying qi and benefiting qi. Adjuvant drugs such as fried perilla fruit, pepperweed, ginger magnolia bark, rhizoma pinelliae preparata, radix curcumae, thunberg fritillary bulb and the like are supplemented to assist the efficacy of monarch drugs and ministerial drugs, and schisandra chinensis, polygala tenuifolia, epimedium and dried orange peel are used as conductant drugs to coordinate the drugs. The preparation can effectively shorten the course of acute exacerbation of the obstructive pulmonary disease and obviously improve the clinical symptoms of patients.